Eisai

Eisai ranks 6th on the list of the largest Japanese pharmaceutical companies. Eisai Co., Ltd. is a Japanese pharmaceutical firm headquartered in Tokyo, Japan. It employs around 10,000 people, with roughly 1,500 working in research. Eisai is traded on the Tokyo Stock Exchange and is a component of the Topix 100 and Nikkei 225 stock indices. Eisai has marketing operations in 19 European nations as well as the Asia-Pacific area.

Eisai Co. Ltd. discovers, develops, manufactures, and markets pharmaceuticals, including prescription drugs, over-the-counter drugs, and generics. Neurology and oncology are two of the company's research franchises. Eisai’s major products include Pariet/AcipHex, Aricept, Halaven, and Fycompa tablets for the treatment of epilepsy and peripheral neuropathy. Eisai has manufacturing sites in Japan, the United Kingdom, China, and India, as well as laboratories in Japan, the United States, and the United Kingdom; activities in the Americas, Asia and Latin America, EMEA, and Oceania; and overseas sales offices in the United States, Germany, France, China, and South Korea.

Founded: 1941
Headquarters: Tokyo, Japan
Official website: https://www.eisai.com/index.html